Literature DB >> 1934191

Antiviral activity of polyoxomolybdoeuropate PM-104 against human immunodeficiency virus type 1.

Y Inouye1, Y Tokutake, T Yoshida, A Yamamoto, T Yamase, S Nakamura.   

Abstract

A polyoxomolybdoeuropate PM-104 (NH4)12H2[Eu4(MoO4)(H2O)16(Mo7O24)4].13H2O was found to be a potent inhibitor of the growth of human immunodeficiency virus type 1 (HIV-1), a causative agent of acquired immunodeficiency syndrome (AIDS). On the basis of TI50 [median cytotoxic concentration (CC50)/median effective concentration (EC50)], the in vitro anti-HIV-1 activity of PM-104 is favorably comparable to that of a heteropolyoxotungstate PM-19 K7[PTi2W10O40].6H2O, which is one of the most potent HIV-1 inhibitors among the polyoxometalates so far tested. The heteropolyoxomolybdate with a potent anti-HIV-1 activity is introduced for the first time in this communication.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1934191     DOI: 10.1248/cpb.39.1638

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  3 in total

1.  Pharmacokinetics of antiviral polyoxometalates in rats.

Authors:  L Ni; F D Boudinot; S G Boudinot; G W Henson; G E Bossard; S A Martellucci; P W Ash; S P Fricker; M C Darkes; B R Theobald
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

2.  Can polyoxometalates (POMs) prevent of coronavirus 2019-nCoV cell entry? Interaction of POMs with TMPRSS2 and spike receptor domain complexed with ACE2 (ACE2-RBD): Virtual screening approaches.

Authors:  Nahid Shahabadi; Mohammad Mahdavi; Saba Zendehcheshm
Journal:  Inform Med Unlocked       Date:  2022-03-05

3.  Inhibition of Human Immunodeficiency Virus Type 1 Entry by a Keggin Polyoxometalate.

Authors:  Xiaoli Wang; Jiao Wang; Wenmei Zhang; Boye Li; Ying Zhu; Qin Hu; Yishu Yang; Xiaoguang Zhang; Hong Yan; Yi Zeng
Journal:  Viruses       Date:  2018-05-16       Impact factor: 5.048

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.